Childhood medulloblastoma-a single institution's historical perspective on survival and functional morbidity.
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cerebellar Neoplasms
/ mortality
Chemotherapy, Adjuvant
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Infant, Newborn
Male
Medulloblastoma
/ mortality
Neurosurgical Procedures
Radiotherapy, Adjuvant
Recovery of Function
Risk Factors
Chemotherapy,
Functional outcome
Medulloblastoma
Neurosurgery,
Radiotherapy
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
16
05
2019
accepted:
27
09
2019
pubmed:
7
11
2019
medline:
27
10
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
To compare results from a third (1995-2010) cohort of children with medulloblastoma with two previous series (J Neurosurg 86:13-21, 1997; Arch Dis Child 54:200-203, 1979) to analyse the effects of management changes aimed at improving both overall and event-free survivals (OS and EFS) and functional outcomes. Review of neuro-oncology and imaging databases and previously published results. There was no statistically significant improvement in the 5-year OS for 104 children diagnosed 1995-2010, 61.5% (95% CI, 52.9, 71.6), compared with 50% of the 80 children presenting 1980-1990 (J Neurosurg 86:13-21, 1997) (difference 11.5%; 95% CI, 2.8, 25.4). Five-year OS for 96 children suitable for risk-stratification was overall 66% (95% CI, 57.9, 75.8); standard risk 77.8% (95% CI, 67.4, 89.7); high risk < 3 years 50.0% (95% CI, 32.3, 77.5); high risk ≥ 3 years 54.5% (95% CI, 37.2, 79.9); 5-year EFS were standard risk 68.5% (95% CI, 57.2, 82.1); high risk < 3 years 40.0% (95% CI, 23.4, 68.4); and high risk ≥ 3 years 36.4% (95% CI, 20.9, 63.2); overall 55.2% (95% CI, 46.1, 66.1). Of 62/63 ≥ 5-year survivor, 9 died later from tumour relapse and 4 from second malignancy. Functional outcomes of 62 of the 63 ≥ 5-year survivors: 67.7% had educational issues requiring remedial input; 18% restricted mobility indoors and outdoors; 59.7% hearing impairment (42% prescribed aids). 1. Comparison of this single-institution series with its predecessor found that revised chemotherapy and RT protocols and greater accuracy of risk stratification did not result in statistically significant improvements in either survival or treatment-related functional disability. 2. Extended (> 5-year) follow-up is essential if 20% of late deaths from relapse and second malignancies are not to be overlooked.
Identifiants
pubmed: 31686139
doi: 10.1007/s00381-019-04402-x
pii: 10.1007/s00381-019-04402-x
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2327-2338Références
Neurochirurgie. 2018 Aug 24;:
pubmed: 30149928
J Clin Oncol. 2012 Sep 10;30(26):3187-93
pubmed: 22851561
Diagn Pathol. 2019 Apr 9;14(1):29
pubmed: 30967140
Brain Sci. 2017 Oct 21;7(10):
pubmed: 29065490
J Neurooncol. 2017 Mar;132(1):99-107
pubmed: 27981412
J Neurosurg. 1996 Jul;85(1):56-65
pubmed: 8683283
Int J Surg Oncol. 2012;2012:245385
pubmed: 22312539
J Neurosurg Pediatr. 2010 Apr;5(4):329-34
pubmed: 20367335
J Neurosurg. 1997 Jan;86(1):13-21
pubmed: 8988076
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
J Natl Cancer Inst. 2015 Nov 04;107(11):djv353
pubmed: 26538622
J Clin Oncol. 2003 Apr 15;21(8):1581-91
pubmed: 12697884
J Clin Oncol. 2006 Sep 1;24(25):4202-8
pubmed: 16943538
Radiother Oncol. 2014 Apr;111(1):41-6
pubmed: 24630538
Lancet Oncol. 2016 Apr;17(4):484-495
pubmed: 26976201
Arch Dis Child. 1979 Mar;54(3):200-3
pubmed: 434906
J Neurosurg Pediatr. 2010 Apr;5(4):325-6; discussion 326-8
pubmed: 20367334
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Curr Neurol Neurosci Rep. 2008 Mar;8(2):111-3
pubmed: 18460278
J Clin Oncol. 2007 Sep 20;25(27):4239-45
pubmed: 17878477
J Neurooncol. 2015 Sep;124(2):247-53
pubmed: 26024655
Lancet Oncol. 2016 Mar;17(3):258-259
pubmed: 26830376
Acta Neuropathol. 2014 Jul;128(1):151-3
pubmed: 24879579
Radiology. 1969 Dec;93(6):1351-9
pubmed: 4983156
Pediatr Blood Cancer. 2008 Jun;50(6):1169-75
pubmed: 18293379
Cytotherapy. 2016 Sep;18(9):1178-86
pubmed: 27421737
J Neurooncol. 2015 Apr;122(2):321-7
pubmed: 25557108
Curr Opin Oncol. 2013 Nov;25(6):674-81
pubmed: 24076581
Childs Nerv Syst. 2014 Jun;30(6):979-90
pubmed: 24569911
J Clin Oncol. 2009 Feb 1;27(4):566-71
pubmed: 19075266
Bioengineering (Basel). 2018 Sep 23;5(4):
pubmed: 30249036
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
J Clin Oncol. 2005 Nov 1;23(31):7951-7
pubmed: 16258095
Transl Pediatr. 2016 Jan;5(1):5-8
pubmed: 26835399
Clin Cancer Res. 2013 Nov 15;19(22):6305-12
pubmed: 24077351
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):292-300
pubmed: 24239386
Pediatr Blood Cancer. 2013 Aug;60(8):1350-7
pubmed: 23444345
Nat Genet. 2017 May;49(5):780-788
pubmed: 28394352
Neuro Oncol. 2013 Jan;15(1):97-103
pubmed: 23099653
Acta Oncol. 2018 Sep;57(9):1134-1142
pubmed: 29771176
J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273
pubmed: 30835699